-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

ASH Poster Walk on Diversity, Equity, and Inclusion in Hematologic Malignancies and Cell Therapy

Program: ASH Poster Walks
Hematology Disease Topics & Pathways:
Biological therapies, Access To Care, Age Inequities, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Cultural Sensitivity, Disability Inequities, Therapies, Disparities, Equity, Gender Inequities, Implicit Bias, LGBTQ Inequities, Transplantation, Racial Inequities, Diversity, Equity, and Inclusion (DEI), Racism, Representation, Socioeconomic Inequities
Thursday, December 16, 2021: 5:00 PM-6:00 PM
(VIRTUAL PROGRAM)
Please view the recorded poster presentations prior to attending this virtual session:

Although hematopoietic cell transplantation and cellular therapies (TCT) are potentially curative therapies for high-risk or advanced hematologic malignancies, disparities impact the provision of care for TCT candidates and recipients. The ASH Poster Walk on Diversity, Equity, and Inclusion in Hematologic Malignancies and Cell Therapy will highlight work being done to investigate and address factors which impact the provision of care across malignant hematology for racialized patients, those of lower socio-economic status, or other vulnerable groups. The walk will also feature work being done to make the field more inclusive for patients and practitioners across race, ethnicity, sexual orientation, gender identity, socioeconomic status, nationality, and disability. Review of this research will improve participant understanding of disparities in malignant hematology and TCT, which is necessary to identify specific patient groups at risk for compromised care. This information is a pre-requisite to enhance outcomes and care delivery. The poster walk will also serve to connect stakeholders interested in Diversity, Equity, and Inclusion (DEI) in malignant hematology and TCT, and will facilitate discussions on the state of DEI research in the field. We will discuss how such efforts can support critically important work to diversify patient populations, mitigate barriers to care, and maximize the equitable provision of optimal TCT for less or under-privileged groups.

The following abstracts will be featured in this session:

Saving Lives with Pride: Development and Evaluation of Multimedia Resources to Engage Gay, Bisexual, and Queer Men in Canada As Stem Cell Donors, Rupal Hatkar

Racial Disparities in the Diagnostic Evaluation of Multiple Myeloma, Lucia Notardonato

Enrollment and Outcomes of Ethnic Minorities with Multiple Myeloma Treated in UK Myeloma Research Alliance (UK-MRA) Clinical Trials over 18 Years, Rakesh Popat

Acute Myeloid Leukemia (AML) Hospitalizations: Racial Disparity in Outcomes of Patients with Comorbidities, Sara Taveras Alam

Gender Disparities in Myelodysplastic Syndromes: Phenotype, Genotype, and Outcomes, Sara Tinsley-Vance

Ethnicity, Nativity and Outcomes in Burkitt Lymphoma Among US Hispanics: Texas and Florida State Database Study, Snegha Ananth

See more of: ASH Poster Walks